To ensure the ongoing affordability of generic medications for Americans, BCBS is committing $55 million to establish a partnership with Civica Rx to reduce costs of generics for consumers.
Chief Executive Officer of the National Organization for Rare Disorders (NORD), discusses some of the challenges facing the rare disease community, including the perception that drug pricing for orphan drugs is a driving force behind rising drug prices.
The mechanisms of pharmaceutical rebates in Medicare Part D and commercial insurance.
Recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, or preventing a range of diseases. However, patients, providers and payers alike have raised concerns about the affordability and sustainability of these drugs.